Meta-Analysis
Copyright ©The Author(s) 2023.
World J Clin Cases. Oct 26, 2023; 11(30): 7350-7362
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Figure 5
Figure 5 Network meta-analysis of adverse events between risedronate, teriparatide, teriparatide combined with denosumab, zoledronic acid, alendronate and placebo. A: Network structure diagrams of adverse events; B: Heterogeneity of the included studies; C: Forest plot of the adverse events of the drugs compared with placebo; D: Surface under the cumulative ranking curve probabilities of different drugs for adverse events.